13 Most Oversold Healthcare Stocks So Far in 2025

10. Inspire Medical Systems, Inc. (NYSE:INSP)

Relative Strength Index (RSI): 34.57 

Inspire Medical Systems, Inc. (NYSE:INSP), a leader in minimally invasive devices for obstructive sleep apnea (OSA), reported challenges in the commercial rollout of its new Inspire V system. Delays in onboarding treatment centers and navigating reimbursement processes have slowed full patient adoption, with some patients still using the older Inspire IV model, impacting revenue growth in 2025.

Inspire Medical Systems, Inc. (NYSE:INSP) also faces increasing competition from GLP-1 drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, which are FDA-approved for weight management and OSA treatment. These medications, widely marketed directly to consumers, are reducing demand for implantable devices like INSP’s. In response, Inspire revised its 2025 sales forecast to a range of $900–$910 million. CEO Tim Herbert noted that the slower U.S. commercial launch and extended transition to Inspire V will weigh on annual financial performance.

Despite these challenges, Inspire Medical Systems, Inc. (NYSE:INSP)’s Board authorized a $200 million share buyback plan in August 2025, signaling confidence in the company’s long-term prospects. The firm expects a marketing push and expansion of treatment centers in the second half of 2025, which could boost procedure volumes and revenue growth into 2026. Additionally, CFO Rick Buchholz announced plans to depart at year-end, moving into an advisory role to facilitate a smooth leadership transition.